Nuvation Bio Inc
NUVB.N- Latest Trade
- trading lower4.19USD
- Change
- -0.02
- % Change
0.48%Negative
- Day Range
- 3.95 - 4.31
- 52-Week Range
- 3.25 - 10.43
As of Jun 25 2022. Values delayed up to 15 minutes
- Previous Close
- 4.21
- Open
- 4.25
- Volume
- 3,912,992.00
- 3 Month Average Trading Volume
- 17.53
- Shares Out (Mil)
- 219.14
- Market Cap
- 918.37
- Forward P/E --
- Dividend Yield
- -99,999.99
Key Statistics
1.57142857 mean rating - 7 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- -99,999.99
- Price To Book (Quarterly)
- 1.27
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -11.30
- Return On Equity (TTM)
- -11.08
2021 (millions USD)
About Nuvation Bio Inc
Company Information
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing differentiated and novel therapeutic candidates focused on treating patients with cancer. The Company is advancing six wholly owned compounds that have resulted from drug discovery and development programs, which include NUV-422 a cyclin-dependent kinase (CDK) inhibitor, NUV-868 a bromodomain and extra terminal (BET) inhibitor, NUV-569 a Wee1 inhibitor, an A2A adenosine receptor inhibitor program, and a drug-drug conjugate (DDC) platform. Its lead product candidate, NUV-422, is a selective small molecule inhibitor of CDK 2, 4 and 6. Its second product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. It is developing, including NUV-569, NUV-569 is a differentiated oral small molecule selective inhibitor of Wee1 kinase, an important regulator of deoxyribonucleic acid (DNA) damage repair. Its subsidiaries include Nuvation Holdings, LLC and RePharmation Ltd.
Executive Leadership
- Daniel G. Welch
- Independent Chair of the Board
- David T. Hung
- President, Chief Executive Officer, Founder, Director
- Jennifer Fox
- Chief Financial Officer
- Stacy Markel
- Chief People Officer
- Gary Hattersley
- Chief Scientific Officer
- David Hanley
- Chief Technical Operations Officer
- Oleg Nodelman
- Director
- Robert B. Bazemore
- Independent Director
- Kim D. Blickenstaff
- Independent Director
- Kathryn E. Falberg
- Independent Director
- W. Anthony Vernon
- Independent Director
Latest News
- MarketsBlue Apron, Baker Hughes, Luminar, cruise cos
U.S. stock indexes rose on Thursday on strong earnings reports, while bargain hunting boosted mega-cap growth companies after the Nasdaq index plunged into correction territory in the previous session.
- MarketsBooking Holdings, Galera Therapeutics, Chinese stocks
U.S. stock index futures were subdued on Wednesday as the latest reading on inflation solidified bets that the Federal Reserve might announce a speedier wind down of its pandemic-era monetary stimulus later in the day.
- MarketsArena Pharma, Harley-Davidson, U.S. banks, travel stocks
U.S. stocks fell on Monday on worries about the Omicron coronavirus variant ahead of a Federal Reserve meeting later this week, while investors watched Apple close in on $3 trillion in market capitalization.
- MarketsNovavax, Harley-Davidson, Peloton, Arena Pharma
U.S. stocks were set to rise on Monday, led by gains in Apple which neared $3 trillion in market capitalization, while investors braced for a Federal Reserve meeting later this week where it will likely signal faster tapering of monetary stimulus.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,825.70 | -- |
| Copper | 693.65 | 0.33%Negative |
| Brent Crude Oil | 113.12 | -- |
| CBOT Soybeans | 1,609.00 | 0.99%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,911.74 | 3.06%Positive |
| Euro STOXX 50 | 3,533.17 | 2.82%Positive |
| FTSE 100 | 7,208.81 | 2.68%Positive |
| Nikkei 225 | 26,491.97 | 1.23%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes